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Preeclampsia is a common, pregnancy-specific disorder characterized by reduced placental perfusion, endothelial
dysfunction, elevated blood pressure, and proteinuria. The pathogenesis of this heterogeneous disorder is incom-
pletely understood, but it has a familial component, which suggests that one or more common alleles may act as
susceptibility genes. We hypothesized that, in a founder population, the genetic background of preeclampsia might
also show reduced heterogeneity, and we have performed a genomewide scan in 15 multiplex families recruited
predominantly in the Kainuu province in central eastern Finland. We found two loci that exceeded the threshold
for significant linkage: chromosome 2p25, near marker D2S168 (nonparametric linkage [NPL] score 3.77; Pp
) at 21.70 cM, and 9p13, near marker D9S169 (NPL score 3.74; ) at 38.90 cM. In addition,.000761 Pp .000821
there was a locus showing suggestive linkage at chromosome 4q32 between D4S413 and D4S3046 (NPL score
3.13; ) at 163.00 cM. In the present study the susceptibility locus on chromosome 2p25 is clearlyPp .003238
different (21.70 cM) from the locus at 2p12 found in an Icelandic study (94.05 cM) and the locus at 2q23 (144.7
cM) found in an Australian/New Zealand study. The locus at 9p13 has been shown to be a candidate region for
type 2 diabetes in two recently published genomewide scans from Finland and China. The regions on chromosomes
2p25 and 9p13 may harbor susceptibility genes for preeclampsia.
Preeclampsia is a common (3%) disorder of pregnancy,
which, together with thrombosis, is the leading cause of
maternal mortality in the Western world. It is a preg-
nancy-specific vascular disorder characterized by re-
duced placental perfusion, endothelial dysfunction, and
activation of coagulation (Roberts et al. 1989). New-
onset hypertension and proteinuria—the symptoms eas-
iest to recognize—develop in the latter half of pregnancy.
The progression of the disease is unpredictable, some-
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times leading to a convulsive phase, eclampsia. The only
effective treatment in eclampsia is the removal of pla-
centa, often leading to premature delivery. The reduced
placental perfusion due to abnormal implantation and/
or maternal preexisting microvascular disease, such as
diabetes and hypertension, is important in the patho-
physiology. However, the condition also requires sys-
temic maternal response to the reduced placental per-
fusion (Ness and Roberts 1996). This response consists
of activation of maternal endothelium, accompanied by
increased sensitivity of the vasculature to any pressor
agent and decreased perfusion to all organs (Roberts and
Cooper 2001). Many risk factors of preeclampsia, such
as obesity and high blood pressure, increase the risk of
atherosclerosis in later life. Indeed, the risk of dying of
ischemic heart disease has been shown to be increased
in women with a history of preeclampsia (Jonsdottir et
al. 1995).
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Preeclampsia has a clearly familial component (Ches-
ley and Cooper 1986; Arngrimsson et al. 1990). The
incidence of preeclampsia among primigravid women
with a family history of preeclampsia is three times that
among primigravid women without such family history
(Esplin et al. 2001). The central role of the placenta in
the disease process may imply that paternal genes present
in the fetus contribute to the disease process. If a woman
becomes pregnant by a man who has already fathered
a preeclamptic pregnancy with a different woman, her
risk of developing preeclampsia is increased almost two-
fold (Lie et al. 1998). Also, a man born of a pregnancy
complicated by preeclampsia is twice as likely to father
a child from a preeclamptic pregnancy than is a man
born of an unaffected pregnancy. On the other hand,
infrequent concordance among MZ twins does not sup-
port a strong overall genetic effect in this condition
(Thornton and Macdonald 1999; Treloar et al. 2001).
However, the maternal susceptibility genes are likely
to be operative in familial preeclampsia. Identification
of those genes will enhance our understanding of the
disease mechanism and will make it possible to iden-
tify women who are at increased risk for developing
preeclampsia.
The genetics of preeclampsia has been difficult to
study, because the disease occurs only in women who
have reproduced and because its causes are heteroge-
neous. Candidate gene studies of the angiotensinogen
gene, the factor V gene, and the methylenetetrahydro-
folate reductase gene on chromosome 1 and the human
leukocyte antigen and tumor necrosis factor gene fam-
ilies on chromosome 6 have yielded conflicting results
(Broughton Pipkin 1999). However, a whole-genome
linkage study provides powerful means to study disease-
susceptibility genes. In the first genomewide scan for
preeclampsia, a recessive model of inheritance was used
for analysis (Hayward et al. 1992). Two whole-genome
linkage studies have found a maternal susceptibility lo-
cus for preeclampsia on chromosome 2. A significant
locus on 2p13 (to D2S286 at 94.05 cM, )LODp 4.70
was detected in the Icelandic study that also included
patients without proteinuria (Arngrimsson et al. 1999).
With similar criteria, a genomewide scan of families
from Australia and New Zealand showed a suggestive
linkage to 2q (between D2S112 and D2S151 at 144.7
cM, ) (Moses et al. 2000). On the otherLODp 2.58
hand, the genomewide scan of Dutch affected sib-pair
families failed to detect linkage to chromosome 2 (Lach-
meijer et al. 2001). These three studies were not able to
confirm previously suggested linkages to 4q (Harrison
et al. 1997) and 7q36 (Arngrimsson et al. 1997; Guo et
al. 1997).
We performed a genomewide scan on Finnish families
with preeclampsia, with particular emphasis on chro-
mosomes 1, 6, and 2p13. We hypothesized that the ge-
netic mechanisms underlying preeclampsia might have
reduced heterogeneity, because the genetic background
of the Finnish founder subpopulations might be more
uniform than those of outbred populations (de la Cha-
pelle and Wright 1998; Peltonen et al. 1999, 2000; Kere
2001; Laitinen et al. 2001).
Families with preeclampsia were recruited predomi-
nantly from the Kainuu province in central eastern Fin-
land, the location of one of the rural populations that
resulted from the internal migration in the 16th century,
and in the Helsinki region in southern Finland. With the
approval of the local ethical committees, we recruited
the preeclampsia probands by sending letters to the pa-
tients who had been hospitalized with the diagnosis of
severe preeclampsia (see definition below) in their first
pregnancies either in Kainuu Central Hospital, Kajaani,
or the Department of Obstetrics and Gynecology, Hel-
sinki University Central Hospital, Helsinki, between
1988 and 1997, and by advertisements for the study.
Between June 1997 and April 1999, we recruited 15
multiplex families (174 individuals) through the pro-
bands. Pedigrees 1–10 (figs. 1 and 2) were recruited from
the Kainuu region, whereas pedigrees 11–15 were re-
cruited from Helsinki (fig. 3). To verify the origin of
families, we traced the birthplaces of parents and grand-
parents, using church records. All participants gave their
informed written consent. The reproductive medical re-
cords of all women were reviewed to confirm or exclude
the diagnosis. Forty-eight women met the criteria of
preeclampsia in their first pregnancies and one woman
in her second pregnancy. One woman met the criteria
of eclampsia in her first pregnancy. Three families had
two affected individuals, eight families had three af-
fected, two families had four affected, one family had
five affected and one family had seven affected. Severe
preeclampsia was diagnosed in 29 of these 50 women
(58%), including all probands. Thirteen women met the
criteria of gestational hypertension in their first preg-
nancies. Every family was ascertained on the basis of at
least one proteinuric preeclampsia case. Within ascer-
tained families, women who had gestational hyperten-
sion without proteinuria were also considered as affected
under the general criteria, because of the higher likeli-
hood of shared susceptibility genes within families. Pre-
eclampsia was defined as systolic blood pressure 1140
mm Hg or diastolic blood pressure 190 mm Hg in a
woman who was normotensive before 20 wk of gesta-
tion, and the urinary excretion of 0.3 g protein in a
24-h specimen or 1 reading on dipstick in a random
urine determination at least twice with no evidence of
the urinary tract infection. Severe preeclampsia was de-
fined if one of the following criteria was met: systolic
blood pressure 160 mm Hg, diastolic blood pressure
110 mm Hg, or proteinuria 2.0 g in 24 h. Eclampsia
was defined as the occurrence, in a woman with pre-
Figure 1 Pedigrees 1–5 recruited for linkage study from the Kainuu region. Blackened circles indicate preeclamptic and eclamptic women.
Shaded circles indicate women with mild preeclampsia (gestational hypertension). Symbols with a blackened upper right quadrant indicate
children born from preeclamptic pregnancies.
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Figure 2 Pedigrees 6–10 recruited for linkage study from the Kainuu region. Blackened circles indicate preeclamptic and eclamptic women.
Shaded circles indicate women with mild preeclampsia (gestational hypertension). Symbols with a blackened upper right quadrant indicate
children born from preeclamptic pregnancies.
eclampsia, of seizures that could not be attributed to
other causes. Hypertension and proteinuria were con-
firmed to have disappeared 3 mo after delivery. In fam-
ilies that included at least one patient with preeclampsia
or severe preeclampsia, women with gestational hyper-
tension (systolic blood pressure 1140mmHg or diastolic
blood pressure 190 mm Hg in a woman who was nor-
motensive before 20 wk of gestation) without significant
proteinuria (!0.3 g/24 h) were considered to have mild
preeclampsia. As in genomewide scan studies published
elsewhere, we used two diagnostic schemes in the present
study. According to the strict criteria, we included only
preeclamptic and eclamptic women, and, according to
the general criteria, we also included women with mild
preeclampsia (gestational hypertension). Of the affected
women, 79% (50/63) met the strict criteria, and 21%
(13/63) met only the general criteria. Five families (fam-
ilies 4, 9, 10, 13, and 14) contained two women with a
history of gestational hypertension, and three families
(families 2, 7, and 8) contained one woman such a his-
tory (figs. 1–3).
EDTA-treated blood (40 ml) was collected from each
individual. DNA was extracted by a standard nonen-
zymatic method. For the first stage of analysis, geno-
typing was performed in the Finnish Genome Center by
use of 381 polymorphic microsatellite markers fromABI
Prism Linkage Mapping Set–MD10 (Applied Biosys-
tems). The average interval between the markers was 10
cM. DNA (20 ng) was dried on 384-well plates at 37C
overnight before PCR setup with a Tecan Genesis 150
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Figure 3 Pedigrees 11–15 recruited for linkage study from Helsinki. Blackened circles indicate preeclamptic and eclamptic women. Shaded
circles indicate women with mild preeclampsia (gestational hypertension). Symbols with a blackened upper right quadrant indicate children
born from preeclamptic pregnancies.
pipetting robot (Biomatic Technologies). The PCRs were
performed in 5-ml volumes, using reagent concentrations
and temperature profiles as recommended by the reagent
manufacturer (Applied Biosystems). The fluorescence-
labeled PCR products were pooled into 28 panels ac-
cording to the LinkageMapping Set–MD10. The pooled
samples were dialyzed before electrophoresis, and elec-
trophoresis was performed on a MegaBace 1,000-cap-
illary electrophoresis instrument (Molecular Dynamics).
The results were analyzed and alleles were called using
Genetic Profiler v. 1.1 software (Molecular Dynamics).
For the second stage of analysis, we designed 21 addi-
tional markers (table 1) between original genome scan
markers, using the Marshfield comprehensive human ge-
netic map. The PCRs were performed as described
above. For the final analysis, we also included markers
genotyped in the Department of Medical Genetics, Uni-
versity of Helsinki (20 markers on chromosome 1, 15
markers on chromosome 6 [derived from Weber set
6], and 8 markers on chromosome 2, around marker
D2S286, which had the highest nonparametric linkage
[NPL] score in the Icelandic study), which were designed
using the Marshfield comprehensive human genetic map
and clone NHO355F16 (GenBank AC007681). For
these additional markers, PCR was performed in 15-ml
reaction volumes that contained 50 ng of genomic DNA,
together with fluorescently labeled primers. The ampli-
fied PCR products were separated using 4.25% poly-
acrylamide gels run on an ABI 377 sequencer (Applied
Biosystems). Lane tracking and allele calling were per-
formed using GeneScan and Genotyper software (Ap-
plied Biosystems). Two investigators scored all the gels.
The total scan included 435 microsatellite markers.
The data were Mendel checked with Pedmanager and
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Table 1








D2S398 D2S162, D2S168 .74
D2S2199 D2S168, D2S305 .63
D2S149 D2S168, D2S305 .72
D2S220 D2S305, D2S2247 (D2S165) .77
D2S2247 Replacing D2S165 .72
D2S352 D2S2247 (D2S165), D2S367 .82
4:
D4S1579 D4S1575, D4S424 .63
D4S2962 D4S424, D4S413 .82
D4S3046 D4S413, D4S1597 .77
D4S1502 D4S1597, D4S1539 .65
9:
D9S289 D9S1677, D9S1776 .75
D9S1811 D9S1776, D9S1682 .82
D9S1829 D9S1682, D9S290 .77
D9S1863 D9S290, D9S164 .73
D9S169 D9S171, D9S161 .83
D9S319 D9S161, D9S1817 .80
D9S1874 D9S1817, D9S273 .84
15:
D15S1048 D15S1002, D15S165 .84
D15S1010 D15S165, D15S1007 .80
D15S1040 D15S1007, D15S1012 .77
GAAC1C11 D15S1007, D15S1012 .87
Pedcheck softwares, and were haplotyped with Gene-
hunter 2.1 software (Whitehead Institute for Biomedical
Research), to check for double recombinants. Linkage
was assessed by the affecteds-only multipoint NPL anal-
ysis method of Genehunter v. 2.1, because the mode of
inheritance of preeclampsia is unknown. Women who
were not known to be affected or were not confirmed
to have had normal pregnancies or who had not repro-
duced—and all men—were classified as “unknown.”
The threshold for genomewide significant linkage was
determined by simulation according to the principles set
forth by Lander and Kruglyak (1995).
The initial genome scan on 381 markers revealed five
loci when strict criteria were used and six loci when
general criteria were used, thus exceeding an NPL score
of 2. We chose five regions for further mapping with a
denser set of markers (table 1). We found a significant
linkage to chromosome 2p25 near marker D2S168 (NPL
score 3.77; ) at 21.70 cM and to chro-Pp .000761
mosome 9p13 near marker D9S169 (NPL score 3.74;
) at 38.90 cM, and we found suggestivePp .000821
linkage to chromosome 4q32 between D4S413 and
D4S3046 (NPL score 3.13; ) at 163.00 cMPp .003238
and chromosome 9p11 near marker D9S1874 (NPL
score 3.26; ) at 49.90 cM when the generalPp .002456
criteria were used (fig. 4A). Moreover, the following
regions displayed nominal linkage: chromosome 9q33
near marker D9S1811 (NPL score 2.74; )Pp .007436
at 120.80 cM, 9q34 near marker D9S1863 (NPL score
2.18; ) at 134.70 cM, and 15q11 betweenPp .022627
markers D15S1007 and D15S1040 (NPL score 2.00;
) at 24.50 cM.Pp .031434
When the strict criteria were used, the NPL scores
were 2.51 for chromosome 2p25 ( ), 2.22Pp .009919
for 9p13 ( ), and 2.96 for 4q32 (Pp .018194 Pp
) (fig. 4B). In addition, chromosome 9p11 dis-.018194
played nominal linkage (NPL score 2.20; ).Pp .019089
The loci 2p25 and 9p13 correlated in five families
(families 6, 8, 10, 11, and 13) when general criteria were
used and in four families (families 6, 10, 11, and 13)
when strict criteria were used (figs. 1–3). The loci 9p13
and 4q32 correlated in six families (families 1, 2, 6, 11,
12, and 13 when either general or strict criteria were
used (figs. 1, 2, and 3). The loci 2p25 and 4q32 cor-
related in seven families (families 5, 6, 7, 11, 13, 14,
and 15) when general criteria were used and in eight
families (families 5, 6, 7, 10, 11, 13, 14, and 15) when
strict criteria were used (figs. 1, 2, and 3).
The correspondence of the most significant loci in each
family was very good when the results of the two criteria
were compared. The NPL scores for the two most sig-
nificant loci, 2p25 and 9p13, were reduced almost
equally (1.26–1.52) when the strict criteria were used
and number of affecteds was reduced from 63 to 50.
Interestingly, the NPL level for the 4q32 locus was re-
duced by only 0.17 NPL scores, and thus there may be
differences between the effect of the different loci.
In the present genomewide scan for preeclampsia, we
studied 15 families collected, in part, from a founder
subpopulation in Finland, which may offer advantages
for the mapping of complex genetic traits (de la Chapelle
andWright 1998; Peltonen et al. 1999, 2000; Kere 2001;
Laitinen et al. 2001). For maximizing genetic homo-
geneity, we recruited these families predominantly from
Kainuu province in central eastern Finland. As was done
in two other genomewide scans for preeclampsia, one
of subjects from Iceland (Arngrimsson et al. 1999) and
one of subjects from Australia and New Zealand (Moses
et al. 2000), we used both the general criteria, which
included women with prior preeclampsia, eclampsia, or
gestational hypertension, and the strict criteria, which
included women with prior preeclampsia or eclampsia.
We found a significant linkage to chromosome 2p25.
In two recent genomewide scans, the most interesting
regions have also been found on chromosome 2. In the
Icelandic study, the support for the locus on 2p13, with
a LOD score of 4.70, came mostly from two large fam-
ilies, and the most telomeric 2p marker compatible with
linkage in at least one of the families was D2S2368 at
position 89.24 cM in the most recent deCODE linkage
map (Arngrimsson et al. 1999; Kong et al. 2002). In the
Australian/New Zealand study, the most interesting re-
Figure 4 Multipoint NPL analysis results, from chromosomes 2, 4, 9, and 15, for the preeclampsia genomewide scan. A, Results when
the general criteria were used. B, Results when the strict criteria were used. The Y-axis indicates the NPL score. The X-axis indicates the
markers and the length of the chromosome.
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gion was on 2q23, with a LOD score of 2.58; the peak
is telomeric to D2S112 at 145.71 cM in the deCODE
map (Moses et al. 2000). Although the distance between
these two loci is ∼50 cM, the investigators concluded
that it is likely that both studies have detected the same
locus, and the locus has been designated “PEE1,” for
preeclampsia, eclampsia gene-1. We now present evi-
dence for a new locus on 2p that by genetic distance is
unlinked to the previous loci. The 95% CI for our link-
age result already excludes D2S2247 at 50.34 cM
(deCODE map distance), with a peak toward the telo-
mere of 2p. With an almost 40-cM gap between the
confidence limits for the Icelandic and Finnish mapping
results, and nearly 100 cM between the Finnish and the
Australian/New Zealand peak, it is inconceivable that
the three linkage results would detect one and the same
locus. Thus, both the number and locations of pre-
eclampsia-susceptibility gene(s) on chromosome 2 re-
main ambiguous. There are previous examples of the
unexpected mapping of more than one locus on the same
chromosome for a single phenotype, but the nature of
the genes is not known in any of those. It is possible
that members of the same gene family, with partially
redundant and overlapping effects, might account for
such mapping results; indeed, segmental duplications are
prominent at the centromere and on the long arm of
chromosome 2 (Bailey et al. 2002). Alternatively, genes
of the same regulatory pathway may cause highly similar
phenotypes with different map positions (e.g., Kere and
Elomaa 2002).
The second significant finding came from chromosome
9p13. Interestingly, it has been shown to be a candidate
region for type 2 diabetes mellitus in two genomewide
scans from the Botnia region in Finland (Lindgren et al.
2002) and China (Luo et al. 2001). Although no hy-
pertensive phenotype of insulin-resistance syndrome has
been attributed to chromosome 9, other features of this
syndrome (type 2 diabetes mellitus and high-density lipo-
protein cholesterol concentrations) have been linked to
chromosome 9 (Arya et al. 2002; Lindgren et al. 2002).
Phenotype can also change during pregnancy, because
pregnancy itself is a highly insulin-resistant state (Kaaja
et al. 1999).
The suggestive linkage to chromosome 4q32 in the
present study is within the same region that was iden-
tified in the earlier of the two Australian genomewide
scans, which used both parametric and nonparametric
analyses (Harrison et al. 1997). Families in that study
are a subset of the authors’ later genomewide scan
(Moses et al. 2000). Curiously, this finding could not be
replicated in the authors’ later study with a larger family
panel that also included families from New Zealand. It
is possible that increased genetic heterogeneity affected
the result.
We were not able to detect linkage to chromosome
1, which contains some candidate genes for pre-
eclampsia and demonstrates inconclusive findings
such as the angiotensinogen gene (Arngrimsson et al.
1993; Ward et al. 1993; Guo et al. 1997), the factor
V gene (O’Shaughnessy et al. 1999; Watanabe et al.
2001) and the methylenetetrahydrofolate reductase gene
(Sohda et al. 1997; Powers et al. 1999; Laivuori et al.
2000). As with our study of chromosome 1, we used a
higher marker density to study chromosome 6, which
contains the human leukocyte antigen and tumor ne-
crosis factor gene families, but we did not find any link-
age. Also, endothelial nitric oxide synthase on chro-
mosome 7 has been proposed as a strong candidate gene
in pregnancy-induced hypertension (Arngrimsson et al.
1997). The results of the present study gave no support
to this finding in the Finnish population. Furthermore,
the most recently reported genome scan for preeclampsia
of Dutch affected sib pairs did not find any peaks in
these regions (Lachmeijer et al. 2001).
Our results provide evidence for linkage of preeclamp-
sia to chromosome 2p25 and 9p13. Our surprising find-
ing of a separate locus for preeclampsia on chromosome
2p25, distinct from two loci reported in two other ge-
nome scans, requires further investigation.
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